Candel Therapeutics Inc (CADL-Q) Analyst Research & Price Targets - The Globe and Mail

Earnings Estimates

	Current Qtr03/2026	Next Qtr06/2026	Fiscal Yr12/2026	Fiscal Yr12/2027
Average Estimate	$-0.22	$-0.27	$-0.94	$-0.16
Number of Estimates	2	1	3	2
High Estimate	$-0.17	$-0.27	$-0.77	$0.32
Low Estimate	$-0.26	$-0.27	$-1.03	$-0.64
Prior Year	$0.13	$-0.09	$-0.72	$-0.94
Growth Rate Est. (year over year)	-269.23%	-200.00%	-30.56%	+82.98%

Earnings History - Surprises*

	Qtr Ending12/2025	Qtr Ending09/2025	Qtr Ending06/2025	Qtr Ending03/2025
Reported	$-0.54	$-0.21	$-0.09	$0.13
Estimate	$-0.24	$-0.17	$-0.17	$-0.24
Difference	-0.30	-0.04	+0.08	+0.37
Surprise	-125.00%	-23.53%	+47.06%	+154.17%

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

4.33

3 Mths Ago9

4.33

2 Mths Ago9

4.56

1 Mth Ago9

4.40

Current10

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	9	9	9	10
	7	7	7	8
Holds	1	1	2	1
	1	1		1

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

Lululemon appoints long-time Nike executive Heidi O’Neill as new CEO

Bullish on Pembina Pipeline Corp.

How investors should digest the stock market’s ‘sugar high’

Market Factors: Top picks, sector review for income-heavy utilities sector

The most oversold and overbought stocks on the TSX

The highest-yielding stocks on the TSX, plus risk data

Barlow’s Research Roundup: These stocks are biggest winners from oil price volatility

It’s not just Allbirds - another meme-stock season is on the horizon, Vanda Research says